522 articles in this topic
A diabetes drug targeting mitochondria simultaneously reduced liver inflammation and preserved muscle mass in mice with MASH-related sarcopenia.
A 10-year Korean cohort study finds that steady alcohol reduction — not just occasional cutbacks — dramatically lowers major liver outcomes in metabolic-associated liver disease.
A large UK cohort study finds adiposity predicts later dysregulated eating, reversing conventional assumptions about weight gain.
A meta-analysis of 28,525 patients finds preoperative GLP-1 receptor agonist use is not linked to worse lumbar fusion outcomes.
A 5-year real-world study finds CGM-derived glucose metrics — especially declining time in range — are associated with microvascular complications in type 1 diabetes and may add prognostic information beyond HbA1c.
A new narrative review reveals GLP-1 receptor agonists have sweeping urological effects — from raising testosterone to a 4.5x higher erectile dysfunction risk.
A review traces the remarkable path from a desert lizard's venom to semaglutide — and explores emerging uses in inflammatory skin disease.
Hypercapnia — high CO2 from lung disease — triggers mitochondrial loss and metabolic reprogramming in monocytes, revealing a new immune vulnerability.
Quantitative muscle MRI fat fraction tracks disease severity in mitochondrial myopathies, outperforming CK and GDF-15 as a biomarker.
A p53-family transcription factor, TAp63, emerges as a central regulator of lipid and glucose homeostasis with broad metabolic implications.
Belgian endocrinologists argue that GLP-1 and dual incretin therapies need individualized titration protocols to maximize benefit and minimize side effects.
Cryo-EM reveals TM6SF1 binds cholesterol inside lysosomes and regulates mTORC1, a master switch of aging and autophagy.
